Harte-Hanks, Inc. (HHS): Price and Financial Metrics


Harte-Hanks, Inc. (HHS)

Today's Latest Price: $2.69 USD

0.06 (-2.18%)

Updated Jul 10 7:43pm

Add HHS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 57 in Outsourcing - Business Services

See all "A" rated Strong Buy stocks

HHS Stock Summary

  • With a one year PEG ratio of 7,757.96, Harte Hanks Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.68% of US stocks.
  • HHS's price/sales ratio is 167.31; that's higher than the P/S ratio of 97.94% of US stocks.
  • The volatility of Harte Hanks Inc's share price is greater than that of 99.98% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Harte Hanks Inc, a group of peers worth examining would be TRU, GHM, GOOS, BKI, and FSS.
  • HHS's SEC filings can be seen here. And to visit Harte Hanks Inc's official web site, go to www.hartehanks.com.

HHS Stock Price Chart Interactive Chart >

Price chart for HHS

HHS Price/Volume Stats

Current price $2.69 52-week high $3.96
Prev. close $2.75 52-week low $1.10
Day low $2.60 Volume 12,500
Day high $2.79 Avg. volume 21,692
50-day MA $2.68 Dividend yield N/A
200-day MA $2.81 Market Cap 17.33M

Harte-Hanks, Inc. (HHS) Company Bio


Harte-Hanks, Inc. provides various marketing services in the United States and internationally. The company was founded in 1970 and is based in San Antonio, Texas.


HHS Latest News Stream


Event/Time News Detail
Loading, please wait...

HHS Latest Social Stream


Loading social stream, please wait...

View Full HHS Social Stream

Latest HHS News From Around the Web

Below are the latest news stories about Harte Hanks Inc that investors may wish to consider to help them evaluate HHS as an investment opportunity.

Harte Hanks to switch listing to OTCQX

Harte Hanks (HHS) to commence delisting procedure on NYSE in its failure to comply with the continued listing standardsThe company does not plan to appeal to NYSE for continue listing.The shares will begin trading on the OTCQX under the symbol HRTE. Source: Press Release...

Seeking Alpha | July 11, 2020

Harte Hanks, Inc. Announces Suspension Of Trading And Commencement Of NYSE Delisting Procedures; Common Stock Expected To Begin Trading On The OTCQX

Harte Hanks, Inc. (NYSE: HHS) (the "Company" or "Harte Hanks"), a leading data-driven multi-channel marketing solutions firm, today announced the Company was notified by the New York Stock Exchange ("NYSE") on July 9, 2020, that the NYSE had determined to commence proceedings to delist the Company's common stock (the "Common Stock") as a result of the Company's failure to comply with the continued listing standard set forth in Section 802.02B of the NYSE Listed Company Manual to maintain either (i) at least $50 million in stockholders' equity or (ii) at least $50 million in total market capitalization on a 30-trading day average basis. The NYSE will announce a suspension date at such time as (i) the Company does not request a review of...

Yahoo | July 10, 2020

All You Need to Know About Harte-Hanks (HHS) Rating Upgrade to Strong Buy

Harte-Hanks (HHS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

Yahoo | June 5, 2020

Flagship Biosciences chooses Harte Hanks as marketing solutions partner.

Harte Hanks, Inc. (HHS), a leading behavioral marketing company, announced today that it has been selected by Flagship Biosciences to provide strategic marketing solutions in developing a new customer acquisition program. Flagship Biosciences is a leader in technology-driven tissue analysis, and provides expert tissue data insights to pharmaceutical, biotechnology and clinical diagnostic companies. Harte Hanks will be developing a targeted, multi-channel campaign including email, digital advertising and content creation to help Flagship Biosciences engage priority audiences, nurture leads and connect with potential clients.

Yahoo | June 3, 2020

Edited Transcript of HHS earnings conference call or presentation 12-Mar-20 8:30pm GMT

Q4 2019 Harte Hanks Inc Earnings Call

Yahoo | June 3, 2020

Read More 'HHS' Stories Here

HHS Price Returns

1-mo N/A
3-mo N/A
6-mo 27.69%
1-year 5.49%
3-year -73.37%
5-year -93.35%
YTD -24.86%
2019 47.93%
2018 -74.50%
2017 -37.15%
2016 -52.12%
2015 -55.20%

Continue Researching HHS

Here are a few links from around the web to help you further your research on Harte Hanks Inc's stock as an investment opportunity:

Harte Hanks Inc (HHS) Stock Price | Nasdaq
Harte Hanks Inc (HHS) Stock Quote, History and News - Yahoo Finance
Harte Hanks Inc (HHS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8526 seconds.